|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
SundaySafety and immunogenicity of a new formulation of interferon -1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing ms
Background: A new formulation of subcutaneous (s.c.) interferon--1a has been developed (Rebif® New Formulation, RNF), produced without fetal bovine serum and without human serum albumin as an excipient, with the aim of improving injection tolerability, and reducing immunogenicity.
Objectives: This article reports 96-week analyses of a Phase IIIb, open-label study of the safety and immunogenicity of RNF compared with historical (EVIDENCE study) and recent (REGARD study) data on the original formulation. Conclusions: RNF has improved overall immunogenicity and safety profiles compared with the original formulation. Sage Publications CLICK HERE FOR FULL ABSTRACT |